{"id":1010988,"date":"2026-10-16T10:08:18","date_gmt":"2026-10-16T14:08:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/"},"modified":"2026-10-16T10:08:18","modified_gmt":"2026-10-16T14:08:18","slug":"revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/","title":{"rendered":"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.RevBiosciences.com&amp;esheet=54623157&amp;newsitemid=20261016185360&amp;lan=en-US&amp;anchor=Revelation+Biosciences%2C+Inc.&amp;index=1&amp;md5=0b421050ad2f2b93363fd9fe2fb60ba2\">Revelation Biosciences, Inc.<\/a> (NASDAQ: REVB) (the \u201cCompany\u201d or \u201cRevelation\u201d), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company\u2019s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol \u201cREVB.\u201d The CUSIP number for the common stock following the reverse stock split will be 76135L887.<\/p>\n<p>\nThe reverse stock split is intended to increase the market price per share of the Company\u2019s common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company\u2019s warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company\u2019s equity incentive plans.<\/p>\n<p><b>Information for Stockholders<\/b><\/p>\n<p>\nUpon the effectiveness of the reverse stock split, each seven shares of the Company\u2019s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder\u2019s relative interest in the Company\u2019s equity, except to the extent that the reverse stock split would have resulted in a stockholder owning a fractional share. Holders of common stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be rounded up to the nearest whole share. The reverse stock split will not change the par value of the common stock or modify the rights or preferences of the common stock. The Company\u2019s transfer agent, Continental Stock Transfer &amp; Trust Co., will maintain the book-entry records for the Company\u2019s common stock. Registered stockholders holding pre-split shares of the Company\u2019s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to such broker\u2019s particular processes, and will not be required to take any action in connection with the reverse stock split. Continental Stock Transfer &amp; Trust Co. can be reached at (212) 509-4000 or (800)-509-5586.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201coutlook,\u201d and \u201cproject\u201d and other similar expressions. We caution investors that forward-looking statements are based on management\u2019s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth, profitability, and retain its key employees; the possibility that Revelation may be adversely affected by other economic, business, and\/or competitive factors; risks relating to the successful development of Revelation\u2019s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and\/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such studies are positive or whether they can be replicated; the outcome of data collected, including whether the results of such data and\/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation\u2019s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261016185360\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261016185360\/en\/<\/a><\/span><\/p>\n<p>\nMike Porter<br \/>\n<br \/><i>Investor Relations<br \/>\n<\/i><br \/>Porter LeVay &amp; Rose Inc.<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:mike@plrinvest.com\">mike@plrinvest.com<br \/>\n<\/a><\/p>\n<p>Chester Zygmont, III<br \/>\n<br \/><i>Chief Financial Officer<br \/>\n<\/i><br \/>Revelation Biosciences Inc.<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:czygmont@revbiosciences.com\">czygmont@revbiosciences.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261016185360\/en\/2878397\/3\/RevelationBiosciences-Logo-EmailSignature.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Revelation Biosciences, Inc. (NASDAQ: REVB) (the \u201cCompany\u201d or \u201cRevelation\u201d), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company\u2019s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol \u201cREVB.\u201d The CUSIP number for the common stock following the reverse stock split will be 76135L887. The reverse stock split is intended to increase the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1010988","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Revelation Biosciences, Inc. (NASDAQ: REVB) (the \u201cCompany\u201d or \u201cRevelation\u201d), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company\u2019s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol \u201cREVB.\u201d The CUSIP number for the common stock following the reverse stock split will be 76135L887. The reverse stock split is intended to increase the &hellip; Continue reading &quot;Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-16T14:08:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026\",\"datePublished\":\"2026-10-16T14:08:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/\"},\"wordCount\":917,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/\",\"name\":\"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-16T14:08:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/","og_locale":"en_US","og_type":"article","og_title":"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 - Market Newsdesk","og_description":"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 SAN DIEGO&#8211;(BUSINESS WIRE)&#8211;Revelation Biosciences, Inc. (NASDAQ: REVB) (the \u201cCompany\u201d or \u201cRevelation\u201d), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company\u2019s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol \u201cREVB.\u201d The CUSIP number for the common stock following the reverse stock split will be 76135L887. The reverse stock split is intended to increase the &hellip; Continue reading \"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-16T14:08:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026","datePublished":"2026-10-16T14:08:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/"},"wordCount":917,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/","name":"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-16T14:08:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261016185360r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revelation-biosciences-announces-1-for-7-reverse-stock-split-effective-october-20-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1010988"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010988\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1010988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1010988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1010988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}